Upstream Bio, Inc. (UPB) Price & Analysis

Compare

103 Followers

UPB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.14 - $29.46

Previous CloseN/A

Volume32.37K

Average Volume (3M)490.84K

Market Cap

$835.95M

Enterprise Value-$101.40M

Total Cash (Recent Filing)$431.38M

Total Debt (Recent Filing)$1.70M

Price to Earnings (P/E)―

Beta0.73

Next Earnings

May 06, 2025

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding53,793,700

10 Day Avg. Volume583,774

30 Day Avg. Volume490,837

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.12

Enterprise Value/Revenue-56.77

Enterprise Value/Gross Profit-56.77

Enterprise Value/Ebitda1.31

Forecast

1Y Price Target

$55.00

Price Target Upside252.34% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Trials And ResultsPositive clinical updates from Phase II trials can drive significant upside to current stock valuations.

Efficacy And DosingThe efficacy of Tezspire exceeds other biologics in CRSwNP and patient preference for every-six-month subcutaneous dosing is higher than daily orals.

Innovative Treatment ApproachVerekitug is the only therapy in development targeting the TSLP receptor, differentiating it from current biologic treatment options.

Bears Say

Market CompetitionExternal data from other competitive TSLP approaches like Tezspire is expected to provide further validation for Upstream Bio's developments.

Safety ConcernsAn unexpected safety signal is considered the worst case for shares and could send the stock towards or even below cash levels.

Upstream Bio, Inc. News

3 Best Stocks to Buy Now, 7/23/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

14d ago

EXE

SUN

Upstream Bio management to meet with Piper Sandler

Meetings to be held in CT on July 15 and in New York on July 16 hosted by...

21d ago

UPB

Upstream Bio doses first patient in Phase 2 trial of verekitug in COPD

Upstream Bio (UPB) announced that the first patient has been dosed in the company’s Phase 2 clinical trial...

28d ago

UPB

Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP Treatment

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today....

9d ago

UPB

Promising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory Conditions

Analyst Tessa Romero from J.P. Morgan maintained a Buy rating on Upstream Bio, Inc. and keeping the price...

9d ago

UPB

Promising Outlook for Upstream Bio: Buy Rating Backed by Innovative CRSwNP Treatment and Strategic Leadership

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today....

14d ago

UPB

Six new option listings and two option delistings on July 1st

New option listings for July 1st include AIRO Group Holdings Inc (AIRO), Fortive (FTV), The Marzetti Company (MZTI),...

1M ago

FTV

RGC

Upstream Bio, Inc.: Promising Clinical Developments and Strategic Positioning Drive Buy Rating

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on UPB stock, giving a Buy rating on...

2M ago

UPB

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

2M ago

UPB

Upstream Bio announces presentation of data on verekitug’s TSLP receptor

Upstream Bio (UPB) announced the presentation of translational pharmacology modeling data supporting verekitug’s Thymic Stromal Lymphopoietin, TSLP, receptor...

2M ago

UPB

Upstream Bio Holds 2025 Annual Stockholders Meeting

Upstream Bio, Inc. ( ($UPB) ) just unveiled an update. Upstream Bio, Inc. held its 2025 Annual Meeting...

2M ago

UPB

Upstream Bio appoints Price as CTO

Upstream Bio (UPB) announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Price brings over...

3M ago

UPB

Upstream Bio Advances Verekitug in Clinical Trials

Upstream Bio, Inc. ( ($UPB) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

UPB

Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position

TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today....

3M ago

UPB

UPB FAQ

What was Upstream Bio, Inc.’s price range in the past 12 months?

Upstream Bio, Inc. lowest stock price was $5.14 and its highest was $29.46 in the past 12 months.

What is Upstream Bio, Inc.’s market cap?

Upstream Bio, Inc.’s market cap is $835.95M.

When is Upstream Bio, Inc.’s upcoming earnings report date?

Upstream Bio, Inc.’s upcoming earnings report date is May 06, 2025 which is 91 days ago.

How were Upstream Bio, Inc.’s earnings last quarter?

Currently, no data Available

Is Upstream Bio, Inc. overvalued?

According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Upstream Bio, Inc. pay dividends?

Upstream Bio, Inc. does not currently pay dividends.

What is Upstream Bio, Inc.’s EPS estimate?

Upstream Bio, Inc.’s EPS estimate is -0.5.

How many shares outstanding does Upstream Bio, Inc. have?

Upstream Bio, Inc. has 53,793,700 shares outstanding.

What happened to Upstream Bio, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Upstream Bio, Inc.?

Currently, no hedge funds are holding shares in UPB

Upstream Bio, Inc. Stock Smart Score

Outperform

Company Description

Upstream Bio, Inc.

Upstream Bio, Inc. (UPB) is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases. Operating within the healthcare and life sciences sectors, Upstream Bio specializes in researching and creating biologic products designed to address unmet medical needs. The company's core services include drug development, clinical trials, and collaboration with research institutions to advance its therapeutic pipeline.

Upstream Bio, Inc. (UPB) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

UPB Earnings Data >

UPB Stock 12 Month Forecast

Average Price Target

$55.00

▲(252.34%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","41":"$41","76":"$76","23.5":"$23.5","58.5":"$58.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,23.5,41,58.5,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.79,15.72923076923077,20.66846153846154,25.60769230769231,30.54692307692308,35.48615384615385,40.425384615384615,45.36461538461539,50.30384615384616,55.24307692307693,60.182307692307695,65.12153846153848,70.06076923076924,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.79,14.19076923076923,17.591538461538462,20.99230769230769,24.393076923076922,27.793846153846154,31.194615384615382,34.59538461538462,37.996153846153845,41.39692307692307,44.79769230769231,48.19846153846154,51.599230769230765,{"y":55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.79,12.65230769230769,14.514615384615384,16.376923076923077,18.23923076923077,20.10153846153846,21.963846153846156,23.826153846153847,25.68846153846154,27.55076923076923,29.413076923076922,31.275384615384617,33.137692307692305,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.38,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.38,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.76,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >